Compare STRIDES PHARMA SCIENCE with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs TTK HEALTHCARE - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE TTK HEALTHCARE STRIDES PHARMA SCIENCE/
TTK HEALTHCARE
 
P/E (TTM) x 14.4 17.1 84.5% View Chart
P/BV x 0.9 1.4 62.3% View Chart
Dividend Yield % 0.6 1.1 50.5%  

Financials

 STRIDES PHARMA SCIENCE   TTK HEALTHCARE
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
TTK HEALTHCARE
Mar-19
STRIDES PHARMA SCIENCE/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,1471,215 94.4%   
Low Rs642610 105.2%   
Sales per share (Unadj.) Rs317.2444.4 71.4%  
Earnings per share (Unadj.) Rs7.817.2 45.5%  
Cash flow per share (Unadj.) Rs25.127.6 90.7%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.20.5 40.8%  
Book value per share (Unadj.) Rs274.3177.9 154.1%  
Shares outstanding (eoy) m89.5014.13 633.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.1 137.3%   
Avg P/E ratio x114.052.9 215.5%  
P/CF ratio (eoy) x35.733.0 108.1%  
Price / Book Value ratio x3.35.1 63.6%  
Dividend payout %25.529.0 87.9%   
Avg Mkt Cap Rs m80,05812,894 620.9%   
No. of employees `0002.52.3 108.4%   
Total wages/salary Rs m4,3411,307 332.1%   
Avg. sales/employee Rs Th11,325.82,715.7 417.0%   
Avg. wages/employee Rs Th1,731.4565.3 306.3%   
Avg. net profit/employee Rs Th280.1105.4 265.7%   
INCOME DATA
Net Sales Rs m28,3946,279 452.2%  
Other income Rs m94178 1,213.7%   
Total revenues Rs m29,3346,356 461.5%   
Gross profit Rs m3,965496 800.1%  
Depreciation Rs m1,540147 1,050.0%   
Interest Rs m1,96234 5,805.9%   
Profit before tax Rs m1,403393 357.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97149 65.3%   
Profit after tax Rs m702244 288.1%  
Gross profit margin %14.07.9 176.9%  
Effective tax rate %6.937.9 18.3%   
Net profit margin %2.53.9 63.7%  
BALANCE SHEET DATA
Current assets Rs m24,8362,717 914.0%   
Current liabilities Rs m18,9931,571 1,209.1%   
Net working cap to sales %20.618.3 112.7%  
Current ratio x1.31.7 75.6%  
Inventory Days Days7132 220.7%  
Debtors Days Days11347 243.1%  
Net fixed assets Rs m34,289991 3,460.0%   
Share capital Rs m895141 633.4%   
"Free" reserves Rs m23,6512,373 996.7%   
Net worth Rs m24,5462,514 976.2%   
Long term debt Rs m15,5133 456,270.6%   
Total assets Rs m65,4374,158 1,573.7%  
Interest coverage x1.712.6 13.6%   
Debt to equity ratio x0.60 46,737.5%  
Sales to assets ratio x0.41.5 28.7%   
Return on assets %4.16.7 61.0%  
Return on equity %2.99.7 29.5%  
Return on capital %6.916.9 40.7%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m15,697225 6,970.3%   
Fx outflow Rs m73571 1,034.2%   
Net fx Rs m14,962154 9,709.7%   
CASH FLOW
From Operations Rs m1,871173 1,080.7%  
From Investments Rs m5,82697 6,037.2%  
From Financial Activity Rs m-10,157-307 3,305.2%  
Net Cashflow Rs m-2,615-38 6,936.0%  

Share Holding

Indian Promoters % 27.7 65.4 42.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 3.7 1,021.6%  
FIIs % 8.6 5.2 165.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 25.8 100.4%  
Shareholders   56,241 12,723 442.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, Indian share markets traded on a volatile note throughout the day and ended marginally higher.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 16, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS